Dako Launches Advanced Staining Platform at Global Pathology Congress
GLOSTRUP, DENMARK -- (Marketwire) -- 03/04/13 -- GLOSTRUP, Denmark,
March 4, 2013 - Dako, an Agilent Technologies Company and worldwide
provider of cancer diagnostics, unveiled the newest addition to
IHC portfolio at the 2013 USCAP congress in Baltimore, Md.,
today. As the exclusive Platinum Sponsor of the congress, Dako used
the opportunity to present
its new advanced staining solution to a
global gathering of pathologists and lab personnel.
The solution, Dako Omnis, comprises hardware, software and reagents.
It automates both IHC and ISH processes, meaning entire patient cases
can be processed simultaneously. This allows pathologists to make
quicker, more informed diagnoses. Oncologists can in turn prescribe
relevant therapy with less
anxiety-ridden waiting time for patients.
"This solution provides a breakthrough in addressing some of the
needs in the anatomic pathology lab," said Dr. Pedro L.
Fernandez of the Hospital Clinic and University of Barcelona, Spain.
"Dako adopted a collaborative approach to bring this solution to
market and cooperated with a
global panel of key independent
laboratory personnel. For over three years, we
have been involved in
the design and development of this solution. Dako has really listened
and responded to the needs of the customer."
"Our customers tell us they are constantly expected to navigate
fluctuating slide numbers with fewer qualified staff and mounting
pressure to provide slides
quickly in order to speed diagnosis," said
Lisa Miller, corporate vice president
of Global Commercial Business,
"With continuous loading, batch loading and overnight run options all
Dako Omnis sets new standards for what customers can
expect from an automated
platform in terms of flexibility, capacity,
efficiency and traceability of slides," she added.
Dako Omnis provides state-of-the-art software to bring lab control to
a new level. Now, key processes such as slide processing and
can be traced to individual operators, greatly
increasing quality control.
As with all Dako's instruments, customers can use the Dako Link
software to connect all solutions and workstations to the
laboratory's own information system. This approach gives the lab
manager even more control over the processing of each individual
slide that enters the lab.
Dako Omnis will be offered as part of Dako's current IHC portfolio,
which includes the Autostainer Link 48 instrument, which Dako will
continue to supply
"Each pathology lab is different, and we believe with the addition of
to our current IHC offering, Dako has an even greater
capability to bring the
right solution to the right customer at the
right time," said Miller. "Dako has
a reputation for bringing firsts
to market, with an unwavering passion for providing quality
solutions. This enables us to offer our customers efficiency,
and more time to ultimately provide better patient care. Advancing
pathology is at the heart of what we do, and our customers tell us
our new platform is an important addition."
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's
software and expertise to make accurate
diagnoses and determine the most effective treatment for cancer
patients. Dako, with 1,200 employees, operates in more than 100
countries. Dako became part of Agilent Technologies on June 21, 2012.
Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier
and a technology leader in chemical analysis, life
sciences, diagnostics, electronics and communications. The company's
20,500 employees serve customers
in more than 100 countries. Agilent
had revenues of $6.9 billion in fiscal 2012. Information about
Agilent is available at www.agilent.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
Director, Science Agenda
Dako Denmark A/S
+45 2933 6980
Press spacebar to pause and continue. Press esc to stop.